RedDress

Company Overview

Snapshot

Founded in April 2009 by Igal Kushnir, RedDress operates with 11–50 employees and has raised $42.5M across 4 funding rounds from 6 investors. The company secured a D Round in May 2023, which was joined by Alpha LTI and HCS Capital.

Business overview

RedDress develops regenerative wound care solutions, with its core product, ActiGraft, being an FDA-cleared technology that enables healthcare providers to create in vitro blood clots from a patient's own blood. These blood clots act as a protective covering and biologic scaffold to promote natural wound-healing processes. The company serves the healthcare industry, focusing on medical devices and medical treatment & therapeutics for patients and providers in the Health Tech & Life Sciences sector.

Strategic signal

In July 2023, RedDress launched ActiGraft PRO with G-Code Reimbursement Status for the US wound care market, a significant development that enhances accessibility and adoption of its regenerative wound care technology. This move signals a strategic expansion within the critical US market, potentially accelerating commercial growth and solidifying the company's position in advanced wound care by simplifying the reimbursement process for healthcare providers.

Company Intelligence Q&A

What is RedDress's core product?

RedDress's core product is ActiGraft, an FDA-cleared regenerative wound care solution. It enables healthcare providers to produce in vitro blood clots from a patient's whole blood to promote natural wound-healing processes.

When did RedDress receive its latest funding?

RedDress received its latest disclosed funding in July 2024 from Katao Venture Partners.

What was a key strategic development for RedDress in late 2022?

In October 2022, RedDress received a Vizient Innovative Technology Contract for its ActiGraft systems, indicating significant market validation and potential for broader adoption within healthcare networks.

Has RedDress expanded its market reach internationally?

Yes, in September 2021, RedDress announced distribution agreements in 12 European countries, expanding its international market presence for its wound care solutions.

What significant regulatory milestone did RedDress achieve in 2021?

In June 2021, RedDress's ActiGraft System received new FDA 510(k) Clearance, further validating its technology and expanding its approved applications.